Mary Caffrey

In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.

In part 2 of our interview with Robinson, he addresses the potential for exacerbated health care disparities in the aftermath of hospital price markups and how insurance plan design often disadvantages the patients who most need expensive infusion therapies but cannot afford them.

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.

In the January issue of The New England Journal of Medicine, James Robinson, PhD, MPH, and his fellow investigators published their findings from an analysis of how insurer drug expenditures on infused drugs influenced price markups at hospitals.

Business and practice updates from our Strategic Alliance Partners.

Coverage from the session, "Bringing Health Equity to Clinical Trials at Every Step," at Patient-Centered Oncology Care 2023.

Coverage from the session, "Which Comes First? Bispecifics, CAR T-Cell Therapy, and Cost Consideration in Sequencing,” at Patient-Centered Oncology Care 2023.

Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."

MD Anderson's Ryan Huey, MD, offers a survey of research on a holistic approach to addressing financial toxicity during Patient Centered Oncology Care 2023.

Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.

Kathryn E. Hudson, MD, of Texas Oncology was a featured speaker at Patient-Centered Oncology Care 2023.

FDA has approved budesonide oral suspension to treat patients 11 years of age and older with eosinophilic esophagitis (EoE). The oral therapy, to be sold as Eohilia, will be available by the end of February, according to sponsor Takeda.

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

Selected coverage of myelodysplastic syndromes and myeloproliferative disease at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of multiple myeloma from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Selected coverage of classical Hodgkin lymphoma (cHL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of mantle cell lymphoma (MCL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer.

The PD-1 inhibitor is being studied in multiple cancers; FDA is reviewing an application of a combination with rivoceranib in unresectable hepatocellular carcinoma.

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

Shifting from an opt-in to an opt-out approach boosted palliative care consults from 16.6% of eligible patients to 43.9%, the investigators found.

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.

Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.